Explore more Articles in

Stock Sectors

US Dollar May Weaken Due to Tariffs, Debt, and Economic Data

Although last week’s US (Non-Farm Payrolls) data beat expectations and gave a slight boost, the rise was not strong enough to change...

Oil Market Shrugs Off OPEC+ Output Increase Amid Strong Demand

Last week, I covered solar energy.   I still say that all energy hands will be needed on deck to support the demands of AI, not...

Oil Market Shrugs Off OPEC+ Supply Increase

managed to settle higher yesterday despite the announced supply increase from OPEC+ Energy – Oil Rallies Despite OPEC+ Supply Increase While prices initially slid yesterday...

May Retail Sales Decline Confirms Eurozone’s Struggles in Q2

The -0.7% month-on-month decline in coincided with a -0.3% decline in overall services activity in April. While surveys had previously indicated potential weakness...
Energy Stocks

Russia Eyes Joint Effort to Steady Shaky Oil Prices

Russia believes that Moscow, its OPEC+ ally Saudi Arabia, and the United States could work together to stabilize the oil market if necessary, the...
Energy Stocks

Why Big Oil Isn’t Afraid of Peak Demand

Major oil companies anticipate that global oil demand will plateau slowly rather than decline sharply, maintaining the need for continued oil and gas production...
Energy Stocks

The Energy Report: Cracking Up

The market is on the verge of another upside breakout as the diesel crack spread is cracking up, hitting the highest level since...
BioTech

Scholar Rock’s Atrophy Drug When Combined With Eli Lilly’s Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study – Scholar Rock Holding...

Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during...
BioTech

Eli Lilly’s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst – Eli Lilly (NYSE:LLY), Verve Therapeutics (NASDAQ:VERV)

On Tuesday, Eli Lilly And Co LLY agreed to acquire Verve Therapeutics, Inc. VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.Lilly...
BioTech

AbbVie’s Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial – AbbVie (NYSE:ABBV)

AbbVie Inc ABBV on Wednesday released topline results from its Phase 3 TEMPLE study evaluating the tolerability, safety, and efficacy of atogepant (QULIPTA/AQUIPTA, 60...
1...222324...29Page 23 of 29

- A word from our sponsors -

Most Popular

Disclaimer: The content provided is for informational purposes only. We aim to keep the content current and accurate by updating it frequently. Sometimes the actual data can differ from what's stated on our website. Buttonwoodnews.com is an independent platform. While we are independent, we may be compensated for advertisements, sponsored products, or when you click on a link on our website. The contributors and authors are not registered or certified financial advisors. You should consult a financial professional before making any financial decisions.

Copyright © Button Wood News.